[1]
Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Experimental biology and medicine (Maywood, N.J.). 2021 May:246(9):1069-1083. doi: 10.1177/1535370221989263. Epub 2021 Feb 7
[PubMed PMID: 33554649]
[2]
Wong CG, Bottiglieri T, Snead OC 3rd. GABA, gamma-hydroxybutyric acid, and neurological disease. Annals of neurology. 2003:54 Suppl 6():S3-12
[PubMed PMID: 12891648]
[3]
Qian X, Zhao X, Yu L, Yin Y, Zhang XD, Wang L, Li JX, Zhu Q, Luo JL. Current status of GABA receptor subtypes in analgesia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Dec:168():115800. doi: 10.1016/j.biopha.2023.115800. Epub 2023 Nov 6
[PubMed PMID: 37935070]
Level 2 (mid-level) evidence
[4]
Benke D. GABA(B) Receptors and Pain. Current topics in behavioral neurosciences. 2022:52():213-239. doi: 10.1007/7854_2020_130. Epub
[PubMed PMID: 32812203]
[5]
Malcangio M, Bowery NG. GABA and its receptors in the spinal cord. Trends in pharmacological sciences. 1996 Dec:17(12):457-62
[PubMed PMID: 9014500]
[6]
Cavalcanti-de-Albuquerque JP, de-Souza-Ferreira E, de Carvalho DP, Galina A. Coupling of GABA Metabolism to Mitochondrial Glucose Phosphorylation. Neurochemical research. 2022 Feb:47(2):470-480. doi: 10.1007/s11064-021-03463-2. Epub 2021 Oct 8
[PubMed PMID: 34623563]
[7]
Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. The Journal of biological chemistry. 2012 Nov 23:287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4
[PubMed PMID: 23038269]
[8]
Kim JJ, Hibbs RE. Direct Structural Insights into GABA(A) Receptor Pharmacology. Trends in biochemical sciences. 2021 Jun:46(6):502-517. doi: 10.1016/j.tibs.2021.01.011. Epub 2021 Mar 3
[PubMed PMID: 33674151]
[9]
Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABA(A) receptors: structure, function, pharmacology, and related disorders. Journal, genetic engineering & biotechnology. 2021 Aug 21:19(1):123. doi: 10.1186/s43141-021-00224-0. Epub 2021 Aug 21
[PubMed PMID: 34417930]
[10]
Goldschen-Ohm MP. Benzodiazepine Modulation of GABA(A) Receptors: A Mechanistic Perspective. Biomolecules. 2022 Nov 30:12(12):. doi: 10.3390/biom12121784. Epub 2022 Nov 30
[PubMed PMID: 36551212]
Level 3 (low-level) evidence
[11]
Padgett CL, Slesinger PA. GABAB receptor coupling to G-proteins and ion channels. Advances in pharmacology (San Diego, Calif.). 2010:58():123-47. doi: 10.1016/S1054-3589(10)58006-2. Epub
[PubMed PMID: 20655481]
Level 3 (low-level) evidence
[12]
Evenseth LSM, Gabrielsen M, Sylte I. The GABA(B) Receptor-Structure, Ligand Binding and Drug Development. Molecules (Basel, Switzerland). 2020 Jul 7:25(13):. doi: 10.3390/molecules25133093. Epub 2020 Jul 7
[PubMed PMID: 32646032]
[14]
Lorenz-Guertin JM, Povysheva N, Chapman CA, MacDonald ML, Fazzari M, Nigam A, Nuwer JL, Das S, Brady ML, Vajn K, Bambino MJ, Weintraub ST, Johnson JW, Jacob TC. Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain. Neurobiology of disease. 2023 Sep:185():106248. doi: 10.1016/j.nbd.2023.106248. Epub 2023 Aug 1
[PubMed PMID: 37536384]
[15]
Zhang D, Pan ZH, Awobuluyi M, Lipton SA. Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends in pharmacological sciences. 2001 Mar:22(3):121-32
[PubMed PMID: 11239575]
[16]
Furukawa T, Fukuda A. Maternal taurine as a modulator of Cl(-) homeostasis as well as of glycine/GABA(A) receptors for neocortical development. Frontiers in cellular neuroscience. 2023:17():1221441. doi: 10.3389/fncel.2023.1221441. Epub 2023 Aug 3
[PubMed PMID: 37601283]
[17]
Wang DD, Kriegstein AR. Defining the role of GABA in cortical development. The Journal of physiology. 2009 May 1:587(Pt 9):1873-9. doi: 10.1113/jphysiol.2008.167635. Epub 2009 Jan 19
[PubMed PMID: 19153158]
[18]
Wu C, Sun D. GABA receptors in brain development, function, and injury. Metabolic brain disease. 2015 Apr:30(2):367-79. doi: 10.1007/s11011-014-9560-1. Epub 2014 May 13
[PubMed PMID: 24820774]
[19]
Perucca E, Bialer M, White HS. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System. CNS drugs. 2023 Sep:37(9):755-779. doi: 10.1007/s40263-023-01027-2. Epub 2023 Aug 21
[PubMed PMID: 37603262]
[20]
Umar Z, Haseeb Ul Rasool M, Muhammad S, Yousaf S, Nassar M, Ilyas U, Hosna AU, Parikh A, Bhangal R, Ahmed N, Ariyaratnam J, Trandafirescu T. Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Cureus. 2023 Jan:15(1):e33695. doi: 10.7759/cureus.33695. Epub 2023 Jan 12
[PubMed PMID: 36788902]
Level 1 (high-level) evidence
[21]
Liu YQ, Yu F, Liu WH, He XH, Peng BW. Dysfunction of hippocampal interneurons in epilepsy. Neuroscience bulletin. 2014 Dec:30(6):985-998. doi: 10.1007/s12264-014-1478-4. Epub 2014 Nov 5
[PubMed PMID: 25370443]
[23]
Schür RR, Draisma LW, Wijnen JP, Boks MP, Koevoets MG, Joëls M, Klomp DW, Kahn RS, Vinkers CH. Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies. Human brain mapping. 2016 Sep:37(9):3337-52. doi: 10.1002/hbm.23244. Epub 2016 May 4
[PubMed PMID: 27145016]
Level 1 (high-level) evidence
[24]
Pearl PL, Hartka TR, Cabalza JL, Taylor J, Gibson MK. Inherited disorders of GABA metabolism. Future neurology. 2006 Sep:1(5):631-636
[PubMed PMID: 23842532]
[25]
Oshi A, Alfaifi A, Seidahmed MZ, Al Hussein K, Miqdad A, Samadi A, Abdelbasit O. GABA transaminase deficiency. Case report and literature review. Clinical case reports. 2021 Mar:9(3):1295-1298. doi: 10.1002/ccr3.3753. Epub 2021 Jan 9
[PubMed PMID: 33768830]
Level 3 (low-level) evidence
[26]
Sjaastad O, Berstad J, Gjesdahl P, Gjessing L. Homocarnosinosis. 2. A familial metabolic disorder associated with spastic paraplegia, progressive mental deficiency, and retinal pigmentation. Acta neurologica Scandinavica. 1976 Apr:53(4):275-90
[PubMed PMID: 1266573]
[27]
Nguyen HN, Chenoweth JA, Bebarta VS, Albertson TE, Nowadly CD. The Toxicity, Pathophysiology, and Treatment of Acute Hydrazine Propellant Exposure: A Systematic Review. Military medicine. 2021 Feb 26:186(3-4):e319-e326. doi: 10.1093/milmed/usaa429. Epub
[PubMed PMID: 33175959]
Level 1 (high-level) evidence
[28]
Vohra V, Dirks A, Bonito G, James T, Carroll DK. A 19-year longitudinal assessment of gyromitrin-containing (Gyromitra spp.) mushroom poisonings in Michigan. Toxicon : official journal of the International Society on Toxinology. 2024 Aug 28:247():107825. doi: 10.1016/j.toxicon.2024.107825. Epub 2024 Jun 20
[PubMed PMID: 38908526]
[29]
Chen X, de Haas S, de Kam M, van Gerven J. An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists. Advances in pharmacological sciences. 2012:2012():134523. doi: 10.1155/2012/134523. Epub 2012 Jan 29
[PubMed PMID: 22363345]
Level 3 (low-level) evidence
[30]
Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, Vahidnia F, Cisse B, Lam J, Alter H. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. The Journal of emergency medicine. 2013 Mar:44(3):592-598.e2. doi: 10.1016/j.jemermed.2012.07.056. Epub 2012 Sep 19
[PubMed PMID: 22999778]
Level 1 (high-level) evidence
[31]
Malone D, Costin BN, MacElroy D, Al-Hegelan M, Thompson J, Bronshteyn Y. Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome. Neuropsychopharmacology reports. 2023 Dec:43(4):532-541. doi: 10.1002/npr2.12347. Epub 2023 Jun 27
[PubMed PMID: 37368937]
[32]
Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol. American journal of critical care : an official publication, American Association of Critical-Care Nurses. 2018 Nov:27(6):454-460. doi: 10.4037/ajcc2018745. Epub
[PubMed PMID: 30385536]
[33]
Shah P, Stegner-Smith KL, Rachid M, Hanif T, Dodd KW. Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2022 Jul:18(3):198-204. doi: 10.1007/s13181-022-00900-8. Epub 2022 Jun 6
[PubMed PMID: 35668289]
[34]
Di Trana A, Beck R, Del Rio A. Management of GHB acute intoxications. La Clinica terapeutica. 2021 Jan-Feb:171(1):e49-e51. doi: 10.7417/CT.2021.2280. Epub
[PubMed PMID: 33346326]
[35]
Drevin G, Rossi LH, Férec S, Briet M, Abbara C. Chemsex/slamsex-related intoxications: A case report involving gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature. Forensic science international. 2021 Apr:321():110743. doi: 10.1016/j.forsciint.2021.110743. Epub 2021 Feb 20
[PubMed PMID: 33640780]
Level 3 (low-level) evidence
[36]
Lee H, Labhardt D, Willmott D. GHB, Chemsex and Chemical Submission: Investigating the Role of Sexuality on Victim Empathy and Blame Attribution in Drug-Facilitated Sexual Assault against Men. Behavioral sciences (Basel, Switzerland). 2024 Oct 8:14(10):. doi: 10.3390/bs14100913. Epub 2024 Oct 8
[PubMed PMID: 39457785]
[37]
Kim GJ, Park SJ, Kim L, Kim KH, Kim S, An JE, Shin CJ, Seo SE, Jo S, Kim J, Ha S, Seo HW, Rho MC, Kwon DH, Kim WK, Jeong G, Ryu JC, Kim JJ, Kwon OS. Second Skin as Self-Protection Against γ-Hydroxybutyrate. ACS nano. 2023 Dec 26:17(24):25405-25418. doi: 10.1021/acsnano.3c08840. Epub 2023 Dec 7
[PubMed PMID: 38060256]
[38]
Berling I, Isoardi K, Harris K, Downes MA, Lovett C, Isbister GK. Growing burden of gamma-hydroxybutyrate intoxication on emergency department resource utilisation. Emergency medicine Australasia : EMA. 2024 Oct:36(5):792-794. doi: 10.1111/1742-6723.14467. Epub 2024 Jul 19
[PubMed PMID: 39030972]
[39]
Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neuroscience and biobehavioral reviews. 1994 Summer:18(2):291-304
[PubMed PMID: 7914688]
Level 3 (low-level) evidence
[40]
Brohan J, Goudra BG. The Role of GABA Receptor Agonists in Anesthesia and Sedation. CNS drugs. 2017 Oct:31(10):845-856. doi: 10.1007/s40263-017-0463-7. Epub
[PubMed PMID: 29039138]
[41]
Hakami T. Neuropharmacology of Antiseizure Drugs. Neuropsychopharmacology reports. 2021 Sep:41(3):336-351. doi: 10.1002/npr2.12196. Epub 2021 Jul 23
[PubMed PMID: 34296824]
[42]
Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15:168():107966. doi: 10.1016/j.neuropharm.2020.107966. Epub 2020 Jan 14
[PubMed PMID: 32120063]
[43]
Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. British journal of pharmacology. 2013 May:169(2):328-36. doi: 10.1111/bph.12127. Epub
[PubMed PMID: 23425285]